A pragmatic analysis of mepolizumab in patients with aspirin-exacerbated respiratory disease

Rationale Aspirin-exacerbated respiratory disease (AERD) is a clinical syndrome defined by chronic eosinophilic rhinosinusitis, nasal polyposis, asthma, and upper and lower respiratory reactions after exposure to cyclooxygenase-1 inhibitors. Conclusions In fourteen patients with AERD, IL-5 inhibitio...

Full description

Saved in:
Bibliographic Details
Published in:Journal of allergy and clinical immunology 2018-02, Vol.141 (2), p.AB168-AB168
Main Authors: Tuttle, Katherine L., Buchheit, Kathleen M., Schneider, Thomas, Hsu Blatman, Karen S., Barrett, Nora A., Laidlaw, Tanya M., Cahill, Katherine N.
Format: Article
Language:English
Subjects:
Aspirin
Asthma
Monoclonal antibodies
Nose
Patients
Respiratory diseases
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c2177-cf5443ee5397919b0418081eeb3daac1afd02f9a033bcc90218ee1ada2f26f0a3
cites
container_end_page AB168
container_issue 2
container_start_page AB168
container_title Journal of allergy and clinical immunology
container_volume 141
creator Tuttle, Katherine L.
Buchheit, Kathleen M.
Schneider, Thomas
Hsu Blatman, Karen S.
Barrett, Nora A.
Laidlaw, Tanya M.
Cahill, Katherine N.
description Rationale Aspirin-exacerbated respiratory disease (AERD) is a clinical syndrome defined by chronic eosinophilic rhinosinusitis, nasal polyposis, asthma, and upper and lower respiratory reactions after exposure to cyclooxygenase-1 inhibitors. Conclusions In fourteen patients with AERD, IL-5 inhibition with mepolizumab for at least 3 months significantly improved both upper and lower airway symptom scores and notably anosmia and nasal congestion, important quality-of-life measures for AERD patients.
doi_str_mv 10.1016/j.jaci.2017.12.537
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2007519918</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0091674917324375</els_id><sourcerecordid>2007519918</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2177-cf5443ee5397919b0418081eeb3daac1afd02f9a033bcc90218ee1ada2f26f0a3</originalsourceid><addsrcrecordid>eNp9kE1LxDAQhoMouK7-AU8Bz62Z9DPgZVn8ggUvehPCNJ1qyvbDpKuuv96U9expmOF9hpmHsUsQMQjIr9u4RWNjKaCIQcZZUhyxBQhVRHkps2O2EEJBlBepOmVn3rci9EmpFux1xUeHbx1O1nDscbv31vOh4R2Nw9b-7DqsuO35GALUT55_2emdox-ts31E32jIVThRzR3NQ5wGt-e19YSeztlJg1tPF391yV7ubp_XD9Hm6f5xvdpERkJRRKbJ0jQhyhJVKFCVSKEUJRBVSY1oAJtayEahSJLKGCUklESANcpG5o3AZMmuDntHN3zsyE-6HXYuPOO1FKLIQCkoQ0oeUsYN3jtq9Ohsh26vQejZom71bFHPFjVIHSwG6OYAUbj_05LT3gQRhmrryEy6Hux_-C-im3zW</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2007519918</pqid></control><display><type>article</type><title>A pragmatic analysis of mepolizumab in patients with aspirin-exacerbated respiratory disease</title><source>Elsevier:Jisc Collections:Elsevier Read and Publish Agreement 2022-2024:Freedom Collection (Reading list)</source><creator>Tuttle, Katherine L. ; Buchheit, Kathleen M. ; Schneider, Thomas ; Hsu Blatman, Karen S. ; Barrett, Nora A. ; Laidlaw, Tanya M. ; Cahill, Katherine N.</creator><creatorcontrib>Tuttle, Katherine L. ; Buchheit, Kathleen M. ; Schneider, Thomas ; Hsu Blatman, Karen S. ; Barrett, Nora A. ; Laidlaw, Tanya M. ; Cahill, Katherine N.</creatorcontrib><description>Rationale Aspirin-exacerbated respiratory disease (AERD) is a clinical syndrome defined by chronic eosinophilic rhinosinusitis, nasal polyposis, asthma, and upper and lower respiratory reactions after exposure to cyclooxygenase-1 inhibitors. Conclusions In fourteen patients with AERD, IL-5 inhibition with mepolizumab for at least 3 months significantly improved both upper and lower airway symptom scores and notably anosmia and nasal congestion, important quality-of-life measures for AERD patients.</description><identifier>ISSN: 0091-6749</identifier><identifier>EISSN: 1097-6825</identifier><identifier>DOI: 10.1016/j.jaci.2017.12.537</identifier><language>eng</language><publisher>St. Louis: Elsevier Inc</publisher><subject>Aspirin ; Asthma ; Monoclonal antibodies ; Nose ; Patients ; Respiratory diseases</subject><ispartof>Journal of allergy and clinical immunology, 2018-02, Vol.141 (2), p.AB168-AB168</ispartof><rights>2017</rights><rights>Copyright Elsevier Science Ltd. Feb 1, 2018</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c2177-cf5443ee5397919b0418081eeb3daac1afd02f9a033bcc90218ee1ada2f26f0a3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids></links><search><creatorcontrib>Tuttle, Katherine L.</creatorcontrib><creatorcontrib>Buchheit, Kathleen M.</creatorcontrib><creatorcontrib>Schneider, Thomas</creatorcontrib><creatorcontrib>Hsu Blatman, Karen S.</creatorcontrib><creatorcontrib>Barrett, Nora A.</creatorcontrib><creatorcontrib>Laidlaw, Tanya M.</creatorcontrib><creatorcontrib>Cahill, Katherine N.</creatorcontrib><title>A pragmatic analysis of mepolizumab in patients with aspirin-exacerbated respiratory disease</title><title>Journal of allergy and clinical immunology</title><description>Rationale Aspirin-exacerbated respiratory disease (AERD) is a clinical syndrome defined by chronic eosinophilic rhinosinusitis, nasal polyposis, asthma, and upper and lower respiratory reactions after exposure to cyclooxygenase-1 inhibitors. Conclusions In fourteen patients with AERD, IL-5 inhibition with mepolizumab for at least 3 months significantly improved both upper and lower airway symptom scores and notably anosmia and nasal congestion, important quality-of-life measures for AERD patients.</description><subject>Aspirin</subject><subject>Asthma</subject><subject>Monoclonal antibodies</subject><subject>Nose</subject><subject>Patients</subject><subject>Respiratory diseases</subject><issn>0091-6749</issn><issn>1097-6825</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNp9kE1LxDAQhoMouK7-AU8Bz62Z9DPgZVn8ggUvehPCNJ1qyvbDpKuuv96U9expmOF9hpmHsUsQMQjIr9u4RWNjKaCIQcZZUhyxBQhVRHkps2O2EEJBlBepOmVn3rci9EmpFux1xUeHbx1O1nDscbv31vOh4R2Nw9b-7DqsuO35GALUT55_2emdox-ts31E32jIVThRzR3NQ5wGt-e19YSeztlJg1tPF391yV7ubp_XD9Hm6f5xvdpERkJRRKbJ0jQhyhJVKFCVSKEUJRBVSY1oAJtayEahSJLKGCUklESANcpG5o3AZMmuDntHN3zsyE-6HXYuPOO1FKLIQCkoQ0oeUsYN3jtq9Ohsh26vQejZom71bFHPFjVIHSwG6OYAUbj_05LT3gQRhmrryEy6Hux_-C-im3zW</recordid><startdate>201802</startdate><enddate>201802</enddate><creator>Tuttle, Katherine L.</creator><creator>Buchheit, Kathleen M.</creator><creator>Schneider, Thomas</creator><creator>Hsu Blatman, Karen S.</creator><creator>Barrett, Nora A.</creator><creator>Laidlaw, Tanya M.</creator><creator>Cahill, Katherine N.</creator><general>Elsevier Inc</general><general>Elsevier Limited</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7SS</scope><scope>7T5</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope></search><sort><creationdate>201802</creationdate><title>A pragmatic analysis of mepolizumab in patients with aspirin-exacerbated respiratory disease</title><author>Tuttle, Katherine L. ; Buchheit, Kathleen M. ; Schneider, Thomas ; Hsu Blatman, Karen S. ; Barrett, Nora A. ; Laidlaw, Tanya M. ; Cahill, Katherine N.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2177-cf5443ee5397919b0418081eeb3daac1afd02f9a033bcc90218ee1ada2f26f0a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Aspirin</topic><topic>Asthma</topic><topic>Monoclonal antibodies</topic><topic>Nose</topic><topic>Patients</topic><topic>Respiratory diseases</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tuttle, Katherine L.</creatorcontrib><creatorcontrib>Buchheit, Kathleen M.</creatorcontrib><creatorcontrib>Schneider, Thomas</creatorcontrib><creatorcontrib>Hsu Blatman, Karen S.</creatorcontrib><creatorcontrib>Barrett, Nora A.</creatorcontrib><creatorcontrib>Laidlaw, Tanya M.</creatorcontrib><creatorcontrib>Cahill, Katherine N.</creatorcontrib><collection>CrossRef</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Premium</collection><jtitle>Journal of allergy and clinical immunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tuttle, Katherine L.</au><au>Buchheit, Kathleen M.</au><au>Schneider, Thomas</au><au>Hsu Blatman, Karen S.</au><au>Barrett, Nora A.</au><au>Laidlaw, Tanya M.</au><au>Cahill, Katherine N.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A pragmatic analysis of mepolizumab in patients with aspirin-exacerbated respiratory disease</atitle><jtitle>Journal of allergy and clinical immunology</jtitle><date>2018-02</date><risdate>2018</risdate><volume>141</volume><issue>2</issue><spage>AB168</spage><epage>AB168</epage><pages>AB168-AB168</pages><issn>0091-6749</issn><eissn>1097-6825</eissn><abstract>Rationale Aspirin-exacerbated respiratory disease (AERD) is a clinical syndrome defined by chronic eosinophilic rhinosinusitis, nasal polyposis, asthma, and upper and lower respiratory reactions after exposure to cyclooxygenase-1 inhibitors. Conclusions In fourteen patients with AERD, IL-5 inhibition with mepolizumab for at least 3 months significantly improved both upper and lower airway symptom scores and notably anosmia and nasal congestion, important quality-of-life measures for AERD patients.</abstract><cop>St. Louis</cop><pub>Elsevier Inc</pub><doi>10.1016/j.jaci.2017.12.537</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0091-6749
ispartof Journal of allergy and clinical immunology, 2018-02, Vol.141 (2), p.AB168-AB168
issn 0091-6749
1097-6825
language eng
recordid cdi_proquest_journals_2007519918
source Elsevier:Jisc Collections:Elsevier Read and Publish Agreement 2022-2024:Freedom Collection (Reading list)
subjects Aspirin
Asthma
Monoclonal antibodies
Nose
Patients
Respiratory diseases
title A pragmatic analysis of mepolizumab in patients with aspirin-exacerbated respiratory disease
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-12T18%3A29%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20pragmatic%20analysis%20of%20mepolizumab%20in%20patients%20with%20aspirin-exacerbated%20respiratory%20disease&rft.jtitle=Journal%20of%20allergy%20and%20clinical%20immunology&rft.au=Tuttle,%20Katherine%20L.&rft.date=2018-02&rft.volume=141&rft.issue=2&rft.spage=AB168&rft.epage=AB168&rft.pages=AB168-AB168&rft.issn=0091-6749&rft.eissn=1097-6825&rft_id=info:doi/10.1016/j.jaci.2017.12.537&rft_dat=%3Cproquest_cross%3E2007519918%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c2177-cf5443ee5397919b0418081eeb3daac1afd02f9a033bcc90218ee1ada2f26f0a3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2007519918&rft_id=info:pmid/&rfr_iscdi=true